J Biol Chem 282 , 2566825676, doi: M702076200 [pii]10.1074/jbc.M702076200 (2007)
No insurance or in-person visits needed
O., Weitzberg, E., Cole, J

For patients at Dwarika Gastro, emphasize monitoring post-stop.[user context][9] Sources [1] Over Half Regain Weight After Stopping GLP-1s [2] Metabolic rebound after GLP-1 receptor agonist discontinuation [3] Semaglutide Treatment Effect in People With Obesity STEP 1 [4] Weight regain and cardiometabolic effects after withdrawal of PMC [5] Weight Loss and Maintenance Related to the Mechanism of Action [6] Weight Reduction with GLP-1 Agonists and Paths for PMC [7] Metabolic rebound after GLP-1 receptor agonist [8] The SURMOUNT-4 Randomized Clinical Trial PubMed [9] Study Reveals Weight Regain Post GLP-1 Receptor Agonist Treatment [10] Why Weight Regain Happens After GLP-1s [11] REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION [12] A Comprehensive Review on Weight Gain following PMC [13] A Post Hoc Analysis of the SURMOUNT-4 Trial PubMed [14] Weight Regain After Liraglutide, Semaglutide or Tirzepatide [15] Weight Maintenance after GLP-1 RA Withdrawal Exposes Critical [16] Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels [17] Rebound or Retention: A Meta-Analysis of Weight Regain After the [18] Semaglutide Treatment Effect in People With Obesity STEP 1 [19] Time to weight plateau with tirzepatide treatment in the PMC Be the first to share your thoughts on this article.
/assets/images/provider/photos/2775905.jpeg)
You'll need to either increase dosing frequency to 3 per week (depleting the vial in 6.6 weeks), increase per-dose amount to 75100mcg (depleting in 57 weeks), or switch to a smaller 0.5mg vial that depletes in 5 weeks at your current protocol